Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-720 inhibitor
- Development stage
- Preclinical
- Lead developer
- UCSF VA Medical Center
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
miR-720 inhibitor is an experimental RNA-based therapeutic designed to silence microRNA-720 (miR-720), a prometastatic microRNA that is significantly upregulated in renal cell carcinoma (RCC). miR-720 promotes cancer progression and the epithelial-to-mesenchymal transition (EMT) by directly targeting and suppressing the expression of the metastasis-suppressing proteins E-cadherin and αE-catenin. By inhibiting miR-720, this agent restores the levels of these suppressors, leading to reduced tumor cell proliferation, migration, and invasion. Preclinical studies in xenograft mouse models have demonstrated that miR-720 inhibition can repress tumor growth and induce apoptosis, while also attenuating oncogenic signaling markers such as β-Catenin, CD44, and Akt.
- Other names
- anti-miR-720anti-miR720anti-miR 720microRNA-720 inhibitormicroRNA720 inhibitormicroRNA 720 inhibitor
Beyond the preview
Go deeper on miR-720 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-720 inhibitor.